Covid vaccine war out in open: Bharat Biotech takes on Serum Institute

Amid questions raised by industry experts and opposition parties on the emergency approval to its coronavirus vaccine Covaxin without publication of efficacy data, Bharat Biotech's chairman on Monday hit out at critics saying his firm had carried out "200 per cent honest clinical trials". Speaking to reporters at a virtual press conference, Krishna Ella said his firm has a track record of producing safe and efficacious vaccines and was transparent with all data. Watch the video for his full reply to his detractors.